amphetaminenote contracted alphamethylphenethylamine central nervous system cns stimulant used treatment attention deficit hyperactivity disorder adhd narcolepsy obesity amphetamine discovered chemical lazÄƒr edeleanu drug late exists two enantiomersnote levoamphetamine dextroamphetamine amphetamine properly refers specific chemical racemic free base equal parts two enantiomers pure amine forms term frequently used informally refer combination enantiomers either alone historically used treat nasal congestion depression amphetamine also used athletic performance enhancer cognitive enhancer recreationally aphrodisiac euphoriant prescription drug many countries unauthorized possession distribution amphetamine often tightly controlled due significant health risks associated recreational usesources first amphetamine pharmaceutical benzedrine brand used treat variety conditions currently pharmaceutical amphetamine prescribed racemic amphetamine adderallnote dextroamphetamine inactive prodrug lisdexamfetamine amphetamine increases monoamine excitatory neurotransmission brain pronounced effects targeting norepinephrine dopamine neurotransmitter systemssources therapeutic doses amphetamine causes emotional cognitive effects euphoria change desire sex increased wakefulness improved cognitive control induces physical effects improved reaction time fatigue resistance increased muscle strength larger doses amphetamine may impair cognitive function induce rapid muscle breakdown addiction serious risk heavy recreational amphetamine use unlikely occur longterm medical use therapeutic doses high doses result psychosis eg delusions paranoia rarely occurs therapeutic doses even longterm use recreational doses generally much larger prescribed therapeutic doses carry far greater risk serious side effectssources amphetamine belongs phenethylamine class also parent compound structural class substituted amphetaminesnote includes prominent substances bupropion cathinone mdma methamphetamine member phenethylamine class amphetamine also chemically related naturally occurring trace amine neuromodulators specifically phenethylamine nmethylphenethylamine produced within human body phenethylamine parent compound amphetamine nmethylphenethylamine positional isomer amphetamine differs placement methyl groupsources amphetamine used treat attention deficit hyperactivity disorder adhd narcolepsy sleep disorder obesity sometimes prescribed offlabel past medical indications particularly depression chronic longterm amphetamine exposure sufficiently high doses animal species known produce abnormal dopamine system development nerve humans adhd longterm use pharmaceutical amphetamines therapeutic doses appears improve brain development nerve reviews magnetic resonance imaging mri studies suggest longterm treatment amphetamine decreases abnormalities brain structure function found subjects adhd improves function several parts brain right caudate nucleus basal reviews clinical stimulant research established safety effectiveness longterm continuous amphetamine use treatment randomized controlled trials continuous stimulant therapy treatment adhd spanning years demonstrated treatment effectiveness two reviews indicated longterm continuous stimulant therapy adhd effective reducing core symptoms adhd ie hyperactivity inattention impulsivity enhancing quality life academic achievement producing improvements large number functional outcomesnote across categories outcomes related academics antisocial behavior driving nonmedicinal drug use obesity occupation selfesteem service use ie academic occupational health financial legal services social one review highlighted ninemonth randomized controlled trial amphetamine treatment adhd children found average increase iq points continued increases attention continued decreases disruptive behaviors another review indicated based upon longest followup studies conducted date lifetime stimulant therapy begins childhood continuously effective controlling adhd symptoms reduces risk developing substance use disorder current models adhd suggest associated functional impairments brains neurotransmitter functional impairments involve impaired dopamine neurotransmission mesocorticolimbic projection norepinephrine neurotransmission noradrenergic projections locus coeruleus prefrontal psychostimulants like methylphenidate amphetamine effective treating adhd increase neurotransmitter activity approximately use stimulants see improvements adhd children adhd use stimulant medications generally better relationships peers family members perform better school less distractible impulsive longer attention cochrane reviewsnote treatment adhd children adolescents adults pharmaceutical amphetamines stated shortterm studies demonstrated drugs decrease severity symptoms higher discontinuation rates nonstimulant medications due adverse side cochrane review treatment adhd children tic disorders tourette syndrome indicated stimulants general make tics worse high doses dextroamphetamine could exacerbate tics systematic review metaanalysis high quality clinical trials found used low therapeutic doses amphetamine produces modest yet unambiguous improvements cognition including working memory longterm episodic memory inhibitory control aspects attention normal healthy cognitionenhancing effects amphetamine known partially mediated indirect activation dopamine receptor adrenoceptor prefrontal systematic review found low doses amphetamine also improve memory consolidation turn leading improved recall therapeutic doses amphetamine also enhance cortical network efficiency effect mediates improvements working memory amphetamine adhd stimulants also improve task saliency motivation perform task increase arousal wakefulness turn promoting goaldirected stimulants amphetamine improve performance difficult boring tasks used students study testtaking based upon studies selfreported illicit stimulant use college students use diverted adhd stimulants primarily used enhancement academic performance rather recreational however high amphetamine doses therapeutic range interfere working memory aspects cognitive amphetamine used athletes psychological athletic performanceenhancing effects increased endurance however nonmedical amphetamine use prohibited sporting events regulated collegiate national international antidoping healthy people oral therapeutic doses amphetamine shown increase muscle strength acceleration athletic performance anaerobic conditions endurance ie delays onset fatigue improving reaction amphetamine improves endurance reaction time primarily reuptake inhibition release dopamine central nervous amphetamine dopaminergic drugs also increase power output fixed levels perceived exertion overriding safety switch allowing core temperature limit increase order access reserve capacity normally therapeutic doses adverse effects amphetamine impede athletic however much higher doses amphetamine induce effects severely impair performance rapid muscle breakdown elevated body amphetamine specifically dopaminergic dextrorotatory enantiomer dextroamphetamine also used recreationally euphoriant aphrodisiac like amphetamines used club drug energetic euphoric high dextroamphetamine damphetamine considered high potential misuse recreational manner since individuals typically report feeling euphoric alert energetic taking notable part mod subculture uk recreational amphetamine use used fuel allnight dances clubs like manchesters twisted wheel newspaper reports described dancers emerging clubs dilated mods used drug stimulation alertness viewed different intoxication caused alcohol dr andrew wilson argues significant minority amphetamines symbolised smart ontheball cool image sought stimulation intoxication greater awareness escape confidence articulacy rather drunken rowdiness previous dextroamphetamines dopaminergic rewarding properties affect mesocorticolimbic circuit group neural structures responsible incentive salience ie wanting desire craving reward motivation positive reinforcement positivelyvalenced emotions particularly ones involving large recreational doses dextroamphetamine may produce symptoms dextroamphetamine recreational users sometimes open dexedrine capsules crush contents order insufflate snort subsequently dissolve water inject immediaterelease formulations higher potential abuse via insufflation snorting intravenous injection due favorable pharmacokinetic profile easy crushability especially injection bloodstream dangerous insoluble fillers within tablets block small blood chronic overuse dextroamphetamine lead severe drug dependence resulting withdrawal symptoms drug use according international programme chemical safety ipcs united states food drug administration usfdanote amphetamine contraindicated people history drug abusenote cardiovascular disease severe agitation severe also contraindicated individuals advanced arteriosclerosis hardening arteries glaucoma increased eye pressure hyperthyroidism excessive production thyroid hormone moderate severe agencies indicate people experienced allergic reactions stimulants taking monoamine oxidase inhibitors maois take although safe concurrent use amphetamine monoamine oxidase inhibitors agencies also state anyone anorexia nervosa bipolar disorder depression hypertension liver kidney problems mania psychosis raynauds phenomenon seizures thyroid problems tics tourette syndrome monitor symptoms taking evidence human studies indicates therapeutic amphetamine use cause developmental abnormalities fetus newborns ie human teratogen amphetamine abuse pose risks amphetamine also shown pass breast milk ipcs usfda advise mothers avoid breastfeeding using due potential reversible growth impairmentsnote usfda advises monitoring height weight children adolescents prescribed amphetamine adverse side effects amphetamine many varied amount amphetamine used primary factor determining likelihood severity adverse amphetamine products adderall dexedrine generic equivalents currently approved usfda longterm therapeutic recreational use amphetamine generally involves much larger doses greater risk serious adverse drug effects dosages used therapeutic cardiovascular side effects include hypertension hypotension vasovagal response raynauds phenomenon reduced blood flow hands feet tachycardia increased heart sexual side effects males may include erectile dysfunction frequent erections prolonged gastrointestinal side effects may include abdominal pain constipation diarrhea potential physical side effects include appetite loss blurred vision dry mouth excessive grinding teeth nosebleed profuse sweating rhinitis medicamentosa druginduced nasal congestion reduced seizure threshold tics type movement disorder weight losssources dangerous physical side effects rare typical pharmaceutical amphetamine stimulates medullary respiratory centers producing faster deeper normal person therapeutic doses effect usually noticeable respiration already compromised may amphetamine also induces contraction urinary bladder sphincter muscle controls urination result difficulty effect useful treating bed wetting loss bladder effects amphetamine gastrointestinal tract intestinal activity high amphetamine may reduce gastrointestinal motility rate content moves digestive however amphetamine may increase motility smooth muscle tract amphetamine also slight analgesic effect enhance pain relieving effects usfdacommissioned studies indicate children young adults adults association serious adverse cardiovascular events sudden death heart attack stroke medical use amphetamine adhd stimulantssources however amphetamine pharmaceuticals contraindicated individuals cardiovascular diseasesources normal therapeutic doses common psychological side effects amphetamine include increased alertness apprehension concentration initiative selfconfidence sociability mood swings elated mood followed mildly depressed mood insomnia wakefulness decreased sense less common side effects include anxiety change libido grandiosity irritability repetitive obsessive behaviors restlessnesssources effects depend users personality current mental amphetamine psychosis eg delusions paranoia occur heavy although rare psychosis also occur therapeutic doses longterm according usfda systematic evidence stimulants produce aggressive behavior amphetamine also shown produce conditioned place preference humans taking therapeutic meaning individuals acquire preference spending time places previously used addiction serious risk heavy recreational amphetamine use unlikely occur longterm medical use therapeutic fact lifetime stimulant therapy adhd begins childhood reduces risk developing substance use disorders pathological overactivation mesolimbic pathway dopamine pathway connects ventral tegmental area nucleus accumbens plays central role amphetamine individuals frequently selfadminister high doses amphetamine high risk developing amphetamine addiction since chronic use high doses gradually increases level accumbal Î´fosb molecular switch master control protein nucleus accumbens Î´fosb sufficiently overexpressed begins increase severity addictive behavior ie compulsive drugseeking increases currently effective drugs treating amphetamine addiction regularly engaging sustained aerobic exercise appears reduce risk developing exercise therapy improves clinical treatment outcomes may used adjunct therapy behavioral therapies chronic use amphetamine excessive doses causes alterations gene expression mesocorticolimbic projection arise transcriptional epigenetic important transcription factorsnote produce alterations delta fbj murine osteosarcoma viral oncogene homolog b Î´fosb camp response element binding protein creb nuclear factorkappa b Î´fosb significant biomolecular mechanism addiction Î´fosb overexpression ie abnormally high level gene expression produces pronounced generelated phenotype medium spiny neurons nucleus accumbens necessary sufficientnote many neural adaptations regulates multiple behavioral effects eg reward sensitization escalating drug selfadministration involved Î´fosb sufficiently overexpressed induces addictive state becomes increasingly severe increases Î´fosb implicated addictions alcohol cannabinoids cocaine methylphenidate nicotine opioids phencyclidine propofol substituted amphetamines among otherssources Î´jund transcription factor histone methyltransferase enzyme oppose function Î´fosb inhibit increases sufficiently overexpressing Î´jund nucleus accumbens viral vectors completely block many neural behavioral alterations seen chronic drug abuse ie alterations mediated similarly accumbal hyperexpression results markedly increased histone lysine residue dimethylation blocks induction Î´fosbmediated neural behavioral plasticity chronic drug usesources occurs via repression transcription factors Î´fosb repression various Î´fosb transcriptional targets eg Î´fosb also plays important role regulating behavioral responses natural rewards palatable food sex since natural rewards addictive drugs induce expression Î´fosb ie cause brain produce chronic acquisition rewards result similar pathological state consequently Î´fosb significant factor involved amphetamine addiction amphetamineinduced sexual addictions compulsive sexual behaviors result excessive sexual activity amphetamine sexual addictions associated dopamine dysregulation syndrome occurs patients taking dopaminergic effects amphetamine gene regulation dose research gene regulation addiction based upon animal studies intravenous amphetamine administration high studies used equivalent weightadjusted human therapeutic doses oral administration show changes occur relatively suggests medical use amphetamine significantly affect gene december effective pharmacotherapy amphetamine reviews indicated agonists significant therapeutic potential treatment psychostimulant however february compounds known function agonists experimental amphetamine addiction largely mediated increased activation dopamine receptors colocalized nmda receptorsnote nucleus magnesium ions inhibit nmda receptors blocking receptor calcium one review suggested based upon animal testing pathological addictioninducing psychostimulant use significantly reduces level intracellular magnesium throughout supplemental magnesiumnote treatment shown reduce amphetamine selfadministration ie doses given oneself humans effective monotherapy amphetamine systematic review metaanalysis assessed efficacy different pharmacotherapies used randomized controlled trials rcts amphetamine methamphetamine found lowstrength evidence methylphenidate might reduce amphetamine methamphetamine low moderatestrength evidence benefit medications used rcts included antidepressants bupropion mirtazapine sertraline antipsychotics aripiprazole anticonvulsants topiramate baclofen gabapentin naltrexone varenicline citicoline ondansetron prometa riluzole atomoxetine dextroamphetamine systematic review network metaanalysis trials involving different psychosocial interventions amphetamine methamphetamine cocaine addiction found combination therapy contingency management community reinforcement approach highest efficacy ie abstinence rate acceptability ie lowest dropout treatment modalities examined analysis included monotherapy contingency management community reinforcement approach cognitive behavioral therapy programs noncontingent rewardbased therapies psychodynamic therapy combination therapies involving additionally research neurobiological effects physical exercise suggests daily aerobic exercise especially endurance exercise eg marathon running prevents development drug addiction effective adjunct therapy ie supplemental treatment amphetamine addictionsources exercise leads better treatment outcomes used adjunct treatment particularly psychostimulant particular aerobic exercise decreases psychostimulant selfadministration reduces reinstatement ie relapse drugseeking induces increased dopamine receptor density opposite pathological stimulant use induces decreased striatal one review noted exercise may also prevent development drug addiction altering Î´fosb cfos immunoreactivity striatum parts reward drug tolerance develops rapidly amphetamine abuse ie recreational amphetamine use periods extended abuse require increasingly larger doses drug order achieve according cochrane review withdrawal individuals compulsively use amphetamine methamphetamine chronic heavy users abruptly discontinue amphetamine use many report timelimited withdrawal syndrome occurs within hours last review noted withdrawal symptoms chronic highdose users frequent occurring roughly cases persist weeks marked crash phase occurring first amphetamine withdrawal symptoms include anxiety drug craving depressed mood fatigue increased appetite increased movement decreased movement lack motivation sleeplessness sleepiness lucid review indicated severity withdrawal symptoms positively correlated age individual extent mild withdrawal symptoms discontinuation amphetamine treatment therapeutic doses avoided tapering amphetamine overdose lead many different symptoms rarely fatal appropriate severity overdose symptoms increases dosage decreases drug tolerance tolerant individuals known take much grams amphetamine day roughly times maximum daily therapeutic symptoms moderate extremely large overdose listed fatal amphetamine poisoning usually also involves convulsions overdose amphetamine methamphetamine compounds implicated amphetamine use disorder resulted estimated deaths worldwide deaths confidencenote rodents primates sufficiently high doses amphetamine cause dopaminergic neurotoxicity damage dopamine neurons characterized dopamine terminal degeneration reduced transporter receptor evidence amphetamine directly neurotoxic however large doses amphetamine may indirectly cause dopaminergic neurotoxicity result hyperpyrexia excessive formation reactive oxygen species increased autoxidation dopaminesources animal models neurotoxicity highdose amphetamine exposure indicate occurrence hyperpyrexia ie core body temperature necessary development amphetamineinduced prolonged elevations brain temperature likely promote development amphetamineinduced neurotoxicity laboratory animals facilitating production reactive oxygen species disrupting cellular protein function transiently increasing barrier amphetamine overdose result stimulant psychosis may involve variety symptoms delusions cochrane review treatment amphetamine dextroamphetamine methamphetamine psychosis states users fail recover according review least one trial shows antipsychotic medications effectively resolve symptoms acute amphetamine psychosis rarely arises therapeutic many types substances known interact amphetamine resulting altered drug action metabolism amphetamine interacting substance inhibitors enzymes metabolize amphetamine eg prolong elimination halflife meaning effects last amphetamine also interacts maois particularly monoamine oxidase inhibitors since maois amphetamine increase plasma catecholamines ie norepinephrine therefore concurrent use amphetamine modulates activity psychoactive drugs particular amphetamine may decrease effects sedatives depressants increase effects stimulants amphetamine may also decrease effects antihypertensives antipsychotics due effects blood pressure dopamine zinc supplementation may reduce minimum effective dose amphetamine used treatment adhdnote general significant interaction consuming amphetamine food ph gastrointestinal content urine affects absorption excretion amphetamine acidic substances reduce absorption amphetamine increase urinary excretion alkaline substances due effect ph absorption amphetamine also interacts gastric acid reducers proton pump inhibitors antihistamines increase gastrointestinal ph ie make less amphetamine exerts behavioral effects altering use monoamines neuronal signals brain primarily catecholamine neurons reward executive function pathways concentrations main neurotransmitters involved reward circuitry executive functioning dopamine norepinephrine increase dramatically dosedependent manner amphetamine effects monoamine reinforcing motivational saliencepromoting effects amphetamine due mostly enhanced dopaminergic activity mesolimbic euphoric locomotorstimulating effects amphetamine dependent upon magnitude speed increases synaptic dopamine norepinephrine concentrations amphetamine identified potent full agonist trace amineassociated receptor gscoupled gqcoupled g proteincoupled receptor gpcr discovered important regulation brain activation increases camptooltip cyclic adenosine monophosphate production via adenylyl cyclase activation inhibits monoamine transporter monoamine autoreceptors eg short presynaptic presynaptic opposite effect together receptors provide regulatory system notably amphetamine trace amines possess high binding affinities monoamine imaging studies indicate monoamine reuptake inhibition amphetamine trace amines site specific depends upon presence colocalization associated monoamine addition neuronal monoamine transporters amphetamine also inhibits vesicular monoamine transporters well excitatory amino acid transporter glutamate transporter located neurons extraneuronal monoamine transporter present astrocytes highaffinity carnitine transportersources amphetamine known strongly induce cocaine amphetamineregulated transcript cart gene neuropeptide involved feeding behavior stress reward induces observable increases neuronal development survival cart receptor yet identified significant evidence cart binds unique gigocoupled amphetamine also inhibits monoamine oxidases high doses resulting less monoamine trace amine metabolism consequently higher concentrations synaptic humans postsynaptic receptor amphetamine known bind receptor acts agonist low micromolar full profile amphetamines shortterm drug effects humans mostly derived increased cellular communication neurotransmission cart endogenous adrenocorticotropic affects interactions cart possibly biological targetssources amphetamine also activates seven human carbonic anhydrase enzymes several expressed human dextroamphetamine potent agonist consequently dextroamphetamine produces greater cns stimulation levoamphetamine roughly three four times levoamphetamine slightly stronger cardiovascular peripheral certain brain regions amphetamine increases concentration dopamine synaptic amphetamine enter presynaptic neuron either dat diffusing across neuronal membrane consequence dat uptake amphetamine produces competitive reuptake inhibition upon entering presynaptic neuron amphetamine activates protein kinase pka protein kinase c pkc signaling causes dat phosphorylation either protein kinase result dat internalization noncompetitive reuptake inhibition pkcmediated phosphorylation alone induces reversal dopamine transport dat ie dopamine effluxnote amphetamine also known increase intracellular calcium effect associated dat phosphorylation unidentified protein kinase camkdependent pathway turn producing dopamine direct activation g proteincoupled inwardlyrectifying potassium channels reduces firing rate dopamine neurons preventing hyperdopaminergic amphetamine also substrate presynaptic vesicular monoamine transporter following amphetamine uptake amphetamine induces collapse vesicular ph gradient results release dopamine molecules synaptic vesicles cytosol via dopamine efflux subsequently cytosolic dopamine molecules released presynaptic neuron synaptic cleft via reverse transport similar dopamine amphetamine dosedependently increases level synaptic norepinephrine direct precursor based upon neuronal mrna expression amphetamine thought affect norepinephrine analogously words amphetamine induces efflux noncompetitive reuptake inhibition phosphorylated net competitive net reuptake inhibition norepinephrine release amphetamine exerts analogous yet less pronounced effects serotonin dopamine amphetamine affects serotonin via like norepinephrine thought phosphorylate sert via like dopamine amphetamine low micromolar affinity human acute amphetamine administration humans increases endogenous opioid release several brain structures reward extracellular levels glutamate primary excitatory neurotransmitter brain shown increase striatum following exposure increase extracellular glutamate presumably occurs via amphetamineinduced internalization glutamate reuptake transporter dopamine amphetamine also induces selective release histamine mast cells efflux histaminergic neurons acute amphetamine administration also increase adrenocorticotropic hormone corticosteroid levels blood plasma stimulating december first study assessing interaction amphetamine human carbonic anhydrase enzymes eleven carbonic anhydrase enzymes examined found amphetamine potently activates seven four highly expressed human brain low nanomolar low micromolar activating based upon preclinical research cerebral carbonic anhydrase activation cognitionenhancing based upon clinical use carbonic anhydrase inhibitors carbonic anhydrase activation tissues may associated adverse effects ocular activation exacerbating oral bioavailability amphetamine varies gastrointestinal well absorbed gut bioavailability typically amphetamine weak base pka consequently ph basic drug lipid soluble free base form absorbed lipidrich cell membranes gut conversely acidic ph means drug predominantly watersoluble cationic salt form less approximately amphetamine circulating bloodstream bound plasma following absorption amphetamine readily distributes tissues body high concentrations occurring cerebrospinal fluid brain halflives amphetamine enantiomers differ vary urine normal urine ph halflives dextroamphetamine levoamphetamine hours hours highly acidic urine reduce enantiomer halflives highly alkaline urine increase halflives immediaterelease extended release variants salts isomers reach peak plasma concentrations hours hours postdose amphetamine eliminated via kidneys drug excreted unchanged normal urinary urinary ph basic amphetamine free base form less urine ph abnormal urinary recovery amphetamine may range low high depending mostly upon whether urine basic acidic following oral administration amphetamine appears urine within roughly ingested amphetamine eliminated days last oral lisdexamfetamine prodrug sensitive ph amphetamine absorbed gastrointestinal following absorption blood stream lisdexamfetamine completely converted red blood cells dextroamphetamine amino acid llysine hydrolysis via undetermined aminopeptidase ratelimiting step bioactivation elimination halflife lisdexamfetamine generally less due necessary conversion lisdexamfetamine dextroamphetamine levels dextroamphetamine lisdexamfetamine peak one hour later equivalent dose immediaterelease presumably due ratelimited activation red blood cells intravenous administration lisdexamfetamine shows greatly delayed time peak reduced peak levels compared intravenous administration equivalent dose pharmacokinetics lisdexamfetamine similar regardless whether administered orally intranasally hence contrast dextroamphetamine parenteral use enhance subjective effects behavior prodrug pharmacokinetic differences lisdexamfetamine longer duration therapeutic effect immediaterelease dextroamphetamine shows reduced misuse dopamine Î²hydroxylase dbh flavincontaining monooxygenase butyratecoa ligase xmligase glycine nacyltransferase glyat enzymes known metabolize amphetamine metabolites humanssources amphetamine variety excreted metabolic products including benzoic acid hippuric acid norephedrine among metabolites active sympathomimetics main metabolic pathways involve aromatic parahydroxylation aliphatic alpha betahydroxylation noxidation ndealkylation known metabolic pathways detectable metabolites metabolizing enzymes humans include following human metagenome ie genetic composition individual microorganisms reside within individuals body varies considerably since total number microbial viral cells human body trillion greatly outnumbers human cells tens trillionsnote considerable potential interactions drugs individuals microbiome including drugs altering composition human microbiome drug metabolism microbial enzymes modifying drugs pharmacokinetic profile microbial drug metabolism affecting drugs clinical efficacy toxicity field studies interactions known similar biomolecules orally administered xenobiotics ie drugs amphetamine predicted undergo promiscuous metabolism human gastrointestinal microbiota primarily bacteria prior absorption blood first amphetaminemetabolizing microbial enzyme tyramine oxidase strain e coli commonly found human gut identified enzyme found metabolize amphetamine tyramine phenethylamine roughly binding affinity three amphetamine similar structure function endogenous trace amines naturally occurring neuromodulator molecules produced human body among group closely related compounds phenethylamine parent compound amphetamine nmethylphenethylamine isomer amphetamine ie identical molecular humans phenethylamine produced directly lphenylalanine aromatic amino acid decarboxylase aadc enzyme converts ldopa dopamine turn nmethylphenethylamine metabolized phenethylamine phenylethanolamine nmethyltransferase enzyme metabolizes norepinephrine like amphetamine phenethylamine nmethylphenethylamine regulate monoamine neurotransmission via unlike amphetamine substances broken monoamine oxidase b therefore shorter halflife amphetamine methyl homolog mammalian neurotransmitter phenethylamine chemical formula carbon atom adjacent primary amine stereogenic center amphetamine composed racemic mixture two racemic mixture separated optical isomersnote levoamphetamine room temperature pure free base amphetamine mobile colorless volatile liquid characteristically strong amine odor acrid burning frequently prepared solid salts amphetamine include amphetamine dextroamphetamine sulfate common enantiopure amphetamine also parent compound structural class includes number psychoactive organic chemistry amphetamine excellent chiral ligand stereoselective synthesis substituted derivatives amphetamine substituted amphetamines broad range chemicals contain amphetamine specifically chemical class includes derivative compounds formed replacing one hydrogen atoms amphetamine core structure class includes amphetamine stimulants like methamphetamine serotonergic empathogens like mdma decongestants like ephedrine among since first preparation reported numerous synthetic routes amphetamine common route legal illicit amphetamine synthesis employs nonmetal reduction known leuckart reaction method first step reaction phenylacetone formamide either using additional formic acid formamide reducing agent yields nformylamphetamine intermediate hydrolyzed using hydrochloric acid subsequently basified extracted organic solvent concentrated distilled yield free base free base dissolved organic solvent sulfuric acid added amphetamine precipitates sulfate number chiral resolutions developed separate two enantiomers example racemic amphetamine treated dtartaric acid form diastereoisomeric salt fractionally crystallized yield chiral resolution remains economical method obtaining optically pure amphetamine large addition several enantioselective syntheses amphetamine developed one example optically pure condensed phenylacetone yield chiral schiff base key step intermediate reduced catalytic hydrogenation transfer chirality carbon atom alpha amino group cleavage benzylic amine bond hydrogenation yields optically pure large number alternative synthetic routes amphetamine developed based classic organic one example alkylation benzene allyl chloride yield beta chloropropylbenzene reacted ammonia produce racemic amphetamine method another example employs ritter reaction method route allylbenzene reacted acetonitrile sulfuric acid yield organosulfate turn treated sodium hydroxide give amphetamine via acetamide third route starts ethyl double alkylation methyl iodide followed benzyl chloride converted acid synthetic intermediate transformed amphetamine using either hofmann curtius rearrangement method significant number amphetamine syntheses feature reduction nitro imine oxime nitrogencontaining functional one example knoevenagel condensation benzaldehyde nitroethane yields double bond nitro group intermediate reduced using either catalytic hydrogenation treatment lithium aluminium hydride method another method reaction phenylacetone ammonia producing imine intermediate reduced primary amine using hydrogen palladium catalyst lithium aluminum hydride method amphetamine frequently measured urine blood part drug test sports employment poisoning diagnostics forensicssources techniques immunoassay common form amphetamine test may crossreact number sympathomimetic chromatographic methods specific amphetamine employed prevent false positive chiral separation techniques may employed help distinguish source drug whether prescription amphetamine prescription amphetamine prodrugs eg selegiline overthecounter drug products contain levomethamphetaminenote illicitly obtained substituted several prescription drugs produce amphetamine metabolite including benzphetamine clobenzorex famprofazone fenproporex lisdexamfetamine mesocarb methamphetamine prenylamine selegiline among compounds may produce positive results amphetamine drug amphetamine generally detectable standard drug test approximately hours although high dose may detectable assays study noted enzyme multiplied immunoassay technique emit assay amphetamine methamphetamine may produce false positives liquid mass gas spectrometry amphetamine methamphetamine derivatizing agent chloride allows detection methamphetamine amphetamine methamphetamine chiral derivatizing agent moshers acid chloride allows detection dextroamphetamine dextromethamphetamine hence latter method may used samples test positive using methods help distinguish various sources amphetamine first synthesized germany romanian chemist lazÄƒr edeleanu named stimulant effects remained unknown independently resynthesized gordon alles reported sympathomimetic amphetamine medical use late smith kline french began selling inhaler brand name benzedrine benzedrine sulfate introduced years later used treat wide variety medical conditions including narcolepsy obesity low blood pressure low libido chronic pain among world war ii amphetamine methamphetamine used extensively allied axis forces stimulant performanceenhancing addictive properties drug became known governments began place strict controls sale example early united states amphetamine became schedule ii controlled substance controlled substances spite strict government controls amphetamine used legally illicitly people variety backgrounds including amphetamine still illegally synthesized today clandestine labs sold black market primarily european among european union eu member states million adults ages used amphetamine methamphetamine least lives million used either last approximately metric tons illicit amphetamine seized within eu member street price illicit amphetamine within eu ranged per gram outside europe illicit market amphetamine much smaller market methamphetamine result united nations convention psychotropic substances amphetamine became schedule ii controlled substance defined treaty state consequently heavily regulated countries south korea japan banned substituted amphetamines even medical nations canada schedule netherlands list united states schedule ii australia schedule thailand category united kingdom class b amphetamine restrictive national drug schedule allows use medical several currently marketed amphetamine formulations contain enantiomers including marketed brand names adderall adderall xr mydayisnote adzenys er adzenys xrodt dyanavel xr evekeo evekeo odt evekeo including evekeo odt product containing racemic amphetamine amphetamine sulfate therefore one whose active moiety accurately referred simply dextroamphetamine marketed brand names dexedrine zenzedi enantiopure amphetamine product currently available prodrug form dextroamphetamine lisdexamfetamine also available marketed brand name vyvanse prodrug lisdexamfetamine structurally different dextroamphetamine inactive metabolizes free base racemic amphetamine previously available benzedrine psychedrine levoamphetamine previously available many current amphetamine pharmaceuticals salts due comparatively high volatility free however oral suspension orally disintegrating tablet odt dosage forms composed free base introduced current brands generic equivalents listed stimulants phenylethanolamine httpsenwikipediaorgwikiamphetamine